Analyst
J.P. Morgan
Equibles does not estimate personal net worth.
Casey Rene Woodring is recorded as Analyst at J.P. Morgan. Casey Rene Woodring has spoken on 10 earnings calls across 9 companies, most recently for Alamar Biosciences, Inc. on August 10, 2026. Those appearances were for Charles River Laboratories International, Inc. (CRL), Alamar Biosciences, Inc. (ALMR), Sotera Health Co (SHC), Qiagen N.V. (QGEN), BillionToOne, Inc. (BLLN) and 4 other companies. The companies whose calls Casey Rene Woodring spoke on are classified in the Healthcare sector.
“Maybe to start, I wanted to ask just on demand trends between academic and pharma customers in the quarter. I know pharma has been driving growth for you guys of late, so just curious if that was the case again, if you could frame up the growth by that customer segment.”
“Maybe just the high-level one here, you know, looking at the guide, you raised the high end after the beat here. I think last year around this time after you beat, you only raised the low end.”
“Maybe just walk through the updated guide for us. You know, I think the back half you took down from 4% to 3% to 4%.”
“Maybe just one, you know, you talked a lot about launching on Epic Aura in the quarter and that, you know, you've integrated faster than any other lab. Is there a scenario where you can be fully integrated by the time we enter 2027.”
“I just wanted to go back to the competitive comments you made about, you know, NHP-related safety assessment studies becoming a competitive advantage for you because you have security of supply.”
J.P. Morgan
Analyst
Transcript header (unverified)
Diagnostics & Research · Healthcare
QGEN
Diagnostics & Research · Healthcare
SHC
Diagnostics & Research · Healthcare
BLLN
Diagnostics & Research · Healthcare
AVTR
Medical Instruments & Supplies · Healthcare
ICLR
Diagnostics & Research · Healthcare
QDEL
Medical Devices · Healthcare
